Log In
Print
BCIQ
Print
Print this Print this
 

Aducanumab (BIIB037)

  Manage Alerts
Collapse Summary General Information
Company Neurimmune Holding AG
DescriptionHuman recombinant anti-beta amyloid mAb
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Biogen Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today